J. Murray

发表

Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637).

Y. Leblanc, H. Jayaram, R. Sims, 2016, ACS medicinal chemistry letters.

Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors.

Adam R. Johnson, Jun Liang, J. DeVoss, 2013, Journal of medicinal chemistry.

Lead identification of novel and selective TYK2 inhibitors.

Adam R. Johnson, Jun Liang, M. Ultsch, 2013, European journal of medicinal chemistry.

Kinetics of relaxation responses to vasorelaxants in isolated rabbit aorta.

H. L. Wiener, J. Murray, G. Thalody, 1992, European journal of pharmacology.

Potent and highly selective benzimidazole inhibitors of PI3-kinase delta.

P. Savy, E. Bradley, M. Ultsch, 2012, Journal of medicinal chemistry.

GNE-371, a Potent and Selective Chemical Probe for the Second Bromodomains of Human Transcription-Initiation-Factor TFIID Subunit 1 and Transcription-Initiation-Factor TFIID Subunit 1-like.

H. Jayaram, F. A. Romero, R. Cummings, 2018, Journal of medicinal chemistry.

Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance.

D. Stokoe, P. Sandy, Steffan Vartanian, 2017, Bioorganic & medicinal chemistry letters.

Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains.

Andrew C Good, Vickie Tsui, Jian Wang, 2016, Journal of medicinal chemistry.

Inhibitory Mechanism of an Allosteric Antibody Targeting the Glucagon Receptor*

I. Hötzel, J. Corn, C. Koth, 2013, The Journal of Biological Chemistry.

Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.

Jane R Kenny, Michael Siu, Deepak Sampath, 2012, Journal of medicinal chemistry.

Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitors.

K. Shoemaker, Z. Ni, S. Cowan-Jacob, 2017, Bioorganic & medicinal chemistry letters.

Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer.

BinQing Wei, D. Sutherlin, L. Friedman, 2011, Journal of medicinal chemistry.

A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) Inhibitors.

Fei Wang, H. Jayaram, F. A. Romero, 2017, Journal of medicinal chemistry.

Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma.

A. Ebens, C. Noland, J. Lyssikatos, 2019, Journal of medicinal chemistry.

GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1.

A. Good, P. Sandy, Y. Leblanc, 2022, Journal of medicinal chemistry.

GNE-886: A Potent and Selective Inhibitor of the Cat Eye Syndrome Chromosome Region Candidate 2 Bromodomain (CECR2).

P. Sandy, H. Jayaram, R. Sims, 2017, ACS medicinal chemistry letters.

Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.

E. Fang, Sylvia Ma, J. Murray, 2006, Bioorganic & medicinal chemistry letters.

The Development of Small-Molecule IAP Antagonists for the Treatment of Cancer

K. Deshayes, J. Murray, D. Vučić, 2012 .

Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300.

Fei Wang, F. A. Romero, E. Choo, 2018, Bioorganic & medicinal chemistry letters.

Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300.

Karen E Gascoigne, Fei Wang, S. Kharbanda, 2016, Journal of medicinal chemistry.

Abstract DDT02-01: Discovery of GDC-0032: A beta-sparing PI3K inhibitor active against PIK3CA mutant tumors.

M. Belvin, E. Bradley, M. Ultsch, 2013 .

Molecular Understanding of USP7 Substrate Recognition and C-Terminal Activation.

J. Ernst, I. Wertz, P. Di Lello, 2016, Structure.

Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelf.

Steve Price, A. Nadin, BinQing Wei, 2013, Bioorganic & medicinal chemistry letters.

Overcoming Preclinical Safety Obstacles to Discover (S)-N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor.

Matthew S. Johnson, M. Ultsch, J. Veal, 2022, Journal of medicinal chemistry.

Optimized arylomycins are a new class of Gram-negative antibiotics

Min Xu, D. Yan, Min Xu, 2018, Nature.

Discovery of 5-Azaindazole (GNE-955) as a Potent Pan-Pim Inhibitor with Optimized Bioavailability.

M. Volgraf, A. Ebens, John G. Moffat, 2017, Journal of medicinal chemistry.

Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.

Bohdan Waszkowycz, Jane R Kenny, Charles Eigenbrot, 2012, Journal of medicinal chemistry.

Cis-amide isosteric replacement in thienobenzoxepin inhibitors of PI3-kinase.

E. Bradley, BinQing Wei, J. Lesnick, 2013, Bioorganic & medicinal chemistry letters.

Structure-based design of thienobenzoxepin inhibitors of PI3-kinase.

D. Sutherlin, S. Sideris, Leslie B. Lee, 2011, Bioorganic & medicinal chemistry letters.

Catalytic mechanism of the quinoenzyme amine oxidase from Escherichia coli: exploring the reductive half-reaction.

M. R. Parsons, M. McPherson, C. Wilmot, 1997, Biochemistry.

Inhibition of Escherichia coli Lipoprotein Diacylglyceryl Transferase Is Insensitive to Resistance Caused by Deletion of Braun’s Lipoprotein

Christian N. Cunningham, Peter S Liu, W. Sandoval, 2021, Journal of bacteriology.

Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.

D. Sutherlin, L. Friedman, Leslie B. Lee, 2010, Bioorganic & medicinal chemistry letters.

Molecular basis for negative regulation of the glucagon receptor

I. Hötzel, A. Estevez, C. Koth, 2012, Proceedings of the National Academy of Sciences.

Optimized arylomycins are a new class of Gram-negative antibiotics

Min Xu, D. Yan, W. Phung, 2018, Nature.

Investigation into the mechanism of λmax shifts and their dependence on pH for the 2-hydrazinopyridine derivatives of two copper amine oxidases

M. McPherson, C. Wilmot, S. Phillips, 2000 .

Structural insights into lipoprotein N-acylation by Escherichia coli apolipoprotein N-acyltransferase

Michele D. Kattke, S. Gloor, D. Yan, 2017, Proceedings of the National Academy of Sciences.

Novel inhibitors of E. coli lipoprotein diacylglyceryl transferase are insensitive to resistance caused by lpp deletion

Christian N. Cunningham, S. Gloor, D. Yan, 2020 .

Unstable Mechanisms of Resistance to Inhibitors of Escherichia coli Lipoprotein Signal Peptidase

Z. Modrušan, L. Komuves, S. Gloor, 2020, mBio.

Targeting the purinome.

D. Bussiere, J. Murray, 2009, Methods in molecular biology.

Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.

Karl A. Merrick, T. O'Brien, A. Jakalian, 2019, Bioorganic & medicinal chemistry letters.

Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.

Pascal Furet, C. Schnell, J. Brueggen, 2011, Journal of medicinal chemistry.

Structurally-defined deubiquitinase inhibitors provide opportunities to investigate disease mechanisms.

I. Wertz, J. Murray, 2019, Drug discovery today. Technologies.

USP7 small-molecule inhibitors interfere with ubiquitin binding

Florian Gnad, Scott E. Martin, Michelle R. Arkin, 2017, Nature.

Palmitoylation of TEAD Transcription Factors Is Required for Their Stability and Function in Hippo Pathway Signaling.

Christian N. Cunningham, P. Schnier, W. Sandoval, 2016, Structure.

Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.

P. Savy, Steve Price, A. Nadin, 2012, Journal of medicinal chemistry.

Allosteric peptides bind a caspase zymogen and mediate caspase tetramerization.

Karen Stanger, R. Hannoush, Y. Franke, 2012, Nature chemical biology.

Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.

Jane R Kenny, Philippe Bergeron, Tian Jin, 2012, Journal of medicinal chemistry.

Tailoring Small Molecules for an Allosteric Site on Procaspase‐6

Xianrui Zhao, Michelle R Arkin, Adam R Renslo, 2013, ChemMedChem.

Mechanistic and Structural Understanding of Uncompetitive Inhibitors of Caspase-6

Brandon J. Bravo, A. Renslo, M. Arkin, 2012, PloS one.

The development of peptide-based tools for the analysis of angiogenesis.

Judith E. Flores, K. Deshayes, Simon-Peter Williams, 2011, Chemistry & biology.

GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP).

Karen E Gascoigne, Y. Ran, G. Hatzivassiliou, 2017, Journal of medicinal chemistry.

Conformational stabilization of ubiquitin yields potent and selective inhibitors of USP7.

Jacob E. Corn, W. Sandoval, J. Corn, 2013, Nature chemical biology.

Targeting cancer: the challenges and successes of structure-based drug design against the human purinome.

D. Bussiere, C. Bellamacina, J. Murray, 2006, Current topics in medicinal chemistry.

Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.

Jane R Kenny, Philippe Bergeron, Charles Eigenbrot, 2012, Bioorganic & medicinal chemistry letters.

Water molecules in protein–ligand interfaces. Evaluation of software tools and SAR comparison

Yong Tang, Eva Nittinger, Paul Gibbons, 2019, Journal of Computer-Aided Molecular Design.

Modulating caspase activity: beyond the active site.

A. Renslo, J. Murray, 2013, Current Opinion in Structural Biology.

Design of Selective Benzoxazepin PI3Kδ Inhibitors Through Control of Dihedral Angles.

A. K. Forrest, BinQing Wei, M. Ultsch, 2017, ACS medicinal chemistry letters.

Identification of GNE-293, a potent and selective PI3Kδ inhibitor: navigating in vitro genotoxicity while improving potency and selectivity.

Steve Price, BinQing Wei, D. Sutherlin, 2013, Bioorganic & medicinal chemistry letters.

Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform.

Steve Price, M. Belvin, BinQing Wei, 2013, Bioorganic & medicinal chemistry letters.

Hydrazine and amphetamine binding to amine oxidases: old drugs with new prospects

M. McPherson, S. Phillips, P. Knowles, 2007, Journal of Neural Transmission.

Probing the catalytic mechanism of Escherichia coli amine oxidase using mutational variants and a reversible inhibitor as a substrate analogue.

M. McPherson, C. Wilmot, S. Phillips, 2002, The Biochemical journal.

Conserved tyrosine-369 in the active site of Escherichia coli copper amine oxidase is not essential.

M. R. Parsons, M. McPherson, C. Wilmot, 2001, Biochemistry.

The active site base controls cofactor reactivity in Escherichia coli amine oxidase: x-ray crystallographic studies with mutational variants.

M. McPherson, C. Wilmot, S. Phillips, 1999, Biochemistry.

Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy.

Melinda M. Mulvihill, R. Rowntree, Wentao Wei, 2021, Journal of medicinal chemistry.

Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors.

A. Ebens, J. Lyssikatos, John G. Moffat, 2015, Bioorganic & medicinal chemistry letters.

Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design.

A. Ebens, John G. Moffat, Richard M Pastor, 2013, Bioorganic & medicinal chemistry letters.

Discovery of Small-Molecule Inhibitors of Ubiquitin Specific Protease 7 (USP7) Using Integrated NMR and in Silico Techniques.

I. Wertz, P. Di Lello, L. Kategaya, 2017, Journal of medicinal chemistry.

Conformational dynamics control ubiquitin-deubiquitinase interactions and influence in vivo signaling

Christian N. Cunningham, W. Forrest, J. Corn, 2013, Proceedings of the National Academy of Sciences.

Limitations to the application of molecularly targeted cancer therapies are the inability to accurately match patient with effective treatment and the absence of a prompt readout of posttreatment response

Judith E. Flores, K. Deshayes, Simon-Peter Williams, 2011 .

Allosteric peptides bind a caspase zymogen and mediate caspase tetramerization.

Karen Stanger, R. Hannoush, Y. Franke, 2012, Nature chemical biology.

Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.

Adam R. Johnson, Rohan V Mendonca, M. Ultsch, 2012, Bioorganic & medicinal chemistry letters.